Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Immune-mediated hypophysitis? 137 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 137 reports of Immune-mediated hypophysitis have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.2% of all adverse event reports for PEMBROLIZUMAB.

137
Reports of Immune-mediated hypophysitis with PEMBROLIZUMAB
0.2%
of all PEMBROLIZUMAB reports
4
Deaths
73
Hospitalizations

How Dangerous Is Immune-mediated hypophysitis From PEMBROLIZUMAB?

Of the 137 reports, 4 (2.9%) resulted in death, 73 (53.3%) required hospitalization, and 22 (16.1%) were considered life-threatening.

Is Immune-mediated hypophysitis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 137 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Immune-mediated hypophysitis?

NIVOLUMAB (171) IPILIMUMAB (135) CARBOPLATIN (59) PACLITAXEL (42) CYCLOPHOSPHAMIDE (33) EPIRUBICIN (23) DURVALUMAB (14) BEVACIZUMAB (12) DOXORUBICIN (11) LENVATINIB (10)

Which PEMBROLIZUMAB Alternatives Have Lower Immune-mediated hypophysitis Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Immune-mediated hypophysitis Reports All Drugs Causing Immune-mediated hypophysitis PEMBROLIZUMAB Demographics